The CHMP recommends approval for JNJs subcutaneous formulation of Rybrevant in NSCLC and AstraZenecas Imfinzi in limited-stage small-cell lung cancer.…
3 February 2025
Transparency Directive
Voting rights and capital
The following notification is made in accordance with the UK Financial Conduct Authoritys Disclosure…